ELI LILLY AND COMPANY Decrease in Unrecognized Tax Benefits is Reasonably Possible
ELI LILLY AND COMPANY (LLY) had Decrease in Unrecognized Tax Benefits is Reasonably Possible of $450.00 million as of 2019-03-31, per its 10-Q filed 2019-05-02.
Discontinued › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible · last filed 2019-10-24
- 2019-03-31: Decrease in Unrecognized Tax Benefits is Reasonably Possible $450.00M.
- 2018-12-31: Decrease in Unrecognized Tax Benefits is Reasonably Possible $450.00M.
- 2015-09-30: Decrease in Unrecognized Tax Benefits is Reasonably Possible $400.00M.
| Period end | Decrease in Unrecognized Tax Benefits is Reasonably Possible |
|---|---|
| 2019-03-31 | $450.00M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $450.00M 8-K · filed 2019-10-24 |
| 2015-09-30 | $400.00M 10-Q · filed 2015-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |